Lupin, Huons ink pact for registration, marketing of Cyclosporine Ophthalmic Nanoemulsion in Mexico
Mumbai: Global pharma major Lupin Limited has announced that it has signed a license and supply agreement with Huons Co. Ltd for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion, 0.4mL Single-use Vial, in Mexico.
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for the treatment of dry eye syndrome and healing corneal ulcers. Its unique nanoparticle technology, can relieve symptoms faster by increasing the tear production in patients with suppressed tear formation due to keratoconjunctivitis sicca-related ocular inflammatory disease.
“We are delighted to partner with Huons to introduce cyclosporine ophthalmic nanoemulsion in Mexico and offer a novel technology that provides significant benefits to our patients suffering from Dry eye. With this addition to our Ophthalmology portfolio, we continue to strengthen our commitment to provide better healthcare and Eyecare solutions to our patients, improving patient quality of life and vision,” said Dr. Fabrice Egros, President – Corporate Development and Growth Markets, Lupin.
Yohun Aum, Senior Director – Head of Global Business Division, Huons said, “Introducing our Cyclosporine Ophthalmic Nanoemulsion in Mexico is a significant milestone for Huons. We look forward to strengthening our partnership by supplying high quality products for Mexico.”
Lupin is a transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.8% of its revenue in research and development in FY24.
Lupin has 15 manufacturing sites, 7 research centers.
Read also: Lupin gets USFDA tentative nod for Sodium Sulfate, Magnesium Sulfate, Potassium Chloride Tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.